TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

▤ Summary

TScan Therapeutics reported positive initial data from Cohort C of its ALLOHA Phase 1 study of TSC-101 in patients undergoing allogeneic hematopoietic cell transplantation. Most patients achieved complete donor chimerism within about three weeks, and the treatment remained well tolerated. The company said the results support its commercial-ready manufacturing process and its planned move into a pivotal Phase 3 study this month. TScan also plans to host a virtual KOL event to discuss the data, the next-stage trial, and the broader market opportunity for its heme program.

▦ Linked Companies